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Abstract
Background: The determinants of malaria parasite virulence is not entirely known, but the outcome of malaria
infection (asymptomatic or symptomatic) has been associated with carriage of distinct parasite genotypes. Alleles
considered important for erythrocyte invasion and selected as candidate targets for malaria vaccine development
are increasingly being shown to have distinct characteristics in infection outcomes. Any unique/distinct patterns or
alleles linked to infection outcome should be reproducible for a given malaria-cohort regardless of location, time or
intervention. This study compared merozoite surface protein 2 (MSP2) genotypes from children with asymptomatic
malaria at same geographical location, from two time periods.
Results: As the prevalence and incidence of malaria (measured for other studies) significantly reduced between
2004 (time point one) and 2009 (time point two), MSP2 multiplicity of infections (MOI) also reduced significantly
from 2.3 at time point (TP) one to 1.9 at TP two. IC/3D7 genotypes out-numbered FC27 genotypes at both time
points. At TP2 however, FC27 allele diversity was more than the IC/3D7 allele diversity. A decrease in the IC/3D7:
FC27 genotype proportions from 2:1 at TP1 to 1:1 at TP2, seemed to be driven mainly by a decrease in carriage of
IC/3D7 alleles. MOI was higher in the dry season than in the subsequent wet season, but the decrease was not
significant at TP2.
Conclusion: MSP2 MOI was higher in the dry season than in the subsequent wet season, while the carriage of IC/
3D7 alleles decreased over this time period. It may be that decreases in transmission are related specifically to the
IC/3D7 allelic family. The influence of transmission on MSP2 allele diversity needs to be clearly deciphered in studies
which should include the use of sensitive methods for the detection of polymorphic parasite markers for both
symptomatic and asymptomatic malaria. Such studies will enable better understanding of associations between
allelic variants, MOI, transmission, malaria infection and disease.
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Background
Reported estimates indicate a decrease in the number of
people infected with malaria parasites from 131 million
in 2010 to 114 million in 2015 and a 29% decrease in
the number of malaria deaths in young children;
nevertheless, malaria mortality remains high among chil-
dren. In 2015, the infection rates were higher in children
between 2 and 10 years of age than in other age groups,
with 70% of the global total of deaths due to malaria
estimated to have occurred in children below 5 years of
age [1]. Malaria caused by Plasmodium falciparum was
responsible for 99% of malaria deaths in 2015, and the
disease ranges in severity from complicated, then mild
(uncomplicated), to asymptomatic [1, 2]. In malaria-
endemic areas, a significant proportion of children
persistently harbour low levels of chronic parasitaemia
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in their blood stream without presenting any signs of
clinical malaria and are considered asymptomatic cases
[3, 4]. Severe (complicated) malaria is the principal cause
of malaria related deaths, nevertheless asymptomatic
malaria also plays an important role [2, 3, 5]. Asymptomatic
malaria poses challenges for malaria control, it signifi-
cantly influences parasite transmission dynamics and
poses a public health danger to an entire population
for as long as mosquito vector distribution and abun-
dance remains [6]. Asymptomatic malaria can provide
clues to understanding protection against clinical
(symptomatic) malaria.
Asexual malaria parasites can be detected in individuals
with either asymptomatic or symptomatic malaria, with
the asymptomatic malaria individuals manifesting no mal-
aria disease, whiles infected individuals with symptomatic
malaria manifest malaria disease [6, 7]. The genetic char-
acteristics of parasite populations detected (in children)
during phases of asymptomatic carriage has been shown
to differ from those causing a symptomatic malaria [8].
Although a number of determinants of parasite virulence
has been proposed [9, 10], the considerable variation in
parasite virulence has also been proposed to be possible
by the absence of competition between the various para-
site “strains” [7, 11]. The ability of P. falciparum to
generate variability within its genetic families has been
shown to be important in modulating the severity of mal-
aria [7, 8, 10, 11]. This variability relies on the extensive
allelic polymorphisms (known to be associated with resist-
ance to antimalarial drugs), the antigenic variation and the
sexual reproduction that ensures genetic mixing [12]. The
number of different P. falciparum allelic variants of a given
loci detected in an individual isolate (although additional al-
leles may easily remain unrecognized) represents the mini-
mum number of the parasite genotypes, commonly
referred to as the multiplicity of infection (MOI) [13]. MOI
measures the number of parasite genotypes, which reflects
recent exposure to infective mosquito bites [14].
The most effective and logistically feasible public
health intervention against most infectious diseases is
vaccination [15]. Rational development of vaccines is
currently approached in two main ways: the sub-unit
approach and the whole organism approach. Sub-unit
vaccines can be made up of multiple or single antigens,
to target the pre-erythrocytic, erythrocytic or sexual-
stage antigens [15, 16]. One of several challenges posed
to the rational development of sub-unit malaria vaccine
is the determination of genetic variants of antigens and/
or their functional mechanisms of protection during
asymptomatic malaria [12, 17, 18]. Following vaccination
with a genetically polymorphic target, it is important for
non-target alleles to remain low. If the frequency of
non-target alleles increases, the efficacy of the vaccine
may be compromised [17]. Fortunately, there is evidence
of associations between parasite alleles and malaria
disease outcome [19–21], giving hope to the possibility
of identifying frequenies of target alleles as well as im-
portant non-target alleles that play a role in malaria in-
fection or disease pre and post vaccination.
Several studies have made it increasingly evident that
parasite alleles considered important to erythrocyte
invasion vary in malaria infection outcomes (symptomatic
or asymptomatic) [22–25]. Asymptomatic carriage of par-
asites has been shown to be associated with reduced risk
of symptomatic malaria [26, 27]. Much of the evidence
seem to support the idea that the outcome of a malaria in-
fection is associated with carriage of unique/variant para-
site alleles. However, there is paucity of information
regarding epidemiological trends for the independent out-
come of infections or the combination of types or number
of parasite alleles associated with the outcome of a malaria
infection. Any unique/distinct patterns or alleles linked to
infection outcome should be reproducible for a given
malaria-cohort regardless of location, time or intervention.
Studies which can determine the consistencies of unique
characteristics in malaria infection outcome will contrib-
ute to the rational development of malaria vaccines. The
determination of consistent pertinent characteristics of al-
leles could be important into setting a platform to argue
for or against categorizing some alleles as either predom-
inantly correlate markers for malaria infection or predom-
inantly correlate markers for malaria disease. Such allele
categorizations could have implications for selecting can-
didate vaccine targets.
The highly polymorphic merozoite surface protein 2 gene
(MSP2) provides opportunity for such investigations.
MSP2, previously known as MSA2, gp35–56, or GP3
[28, 29] play a role in the merozoite invasion of host
erythrocytes and has been strongly associated with protec-
tion against malaria [26]. The several alleles of the MSP2
are grouped under 2 main families – the IC family and
FC27 family. The difference between these two main al-
lelic families are the dimorphic, non-repetitive sequences
internal to the N- and C- termini [30, 31]. MSP2 remains
a candidate antigen (having allele-specific effects) with po-
tential for a subunit malaria vaccine amidst disappointing
results from some trials [32]. In addition, in 2004 the
MSP2 antigen was found to be the most polymorphic of
the 3 polymorphic surface antigens (MSP1, MSP2 and
Glutamate Rich Protein) analysed in the Kintampo area of
Ghana where this study was conducted [33].
This study compared the MSP2 antigen diversity from
children with asymptomatic malaria in 2003/2004 [Time
point (TP1)] and 2009/2010 (TP2) to determine whether
there are significant differences in parasite diversity and/
or any consistently unique or distinct patterns for the
polymorphic MSP2 antigen, at the same geographical
location.
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Methods
Study area
Analysis was carried out on samples collected from
resident community members in the Kintampo North
Municipality and the Kintampo South District at two time
points using molecular biology facilities at the Kintampo
Health Research Centre. The municipality and district lie
within the forest savannah transitional ecological zone in
the middle belt of Ghana. The Kintampo municipality and
district cover an area of 7162 km2 and had a resident
population of 134,970 in 2009 [34]. Mean monthly
temperature ranges between 18 °C and 38 °C with average
rainfall of 1250 mm per annum [33]. Up until 2003 when
the first set of samples were taken for analysis (TP1 study),
chloroquine was the first-line antimalarial drug in use for
treatment of uncomplicated malaria in Ghana. Bed-net
use among children less than 5 years old was 25.4% and
the incidence of malaria in children below 5 years of age
was 7 episodes per child per year [33]. Malaria transmis-
sion was high (entomological inoculation rate: 213 infect-
ive bites per person per year for the year of 2005) and
perennial, peaking between April and October (major
rainy season) and lowest from December to April (major
dry season) of 2004 [35]. The drug policy changed in 2004
with artemisinin-based combination therapy (ACT) be-
coming first line antimalarial. In 2009 when the second
set of samples were taken (TP2 study) for analysis, ACT
use for the treatment of uncomplicated malaria in Ghana/
Kintampo was virtually universal. Bed-net use had in-
creased from 25.4% (measured for children) to 47.4%
(measured for pregnant women), and the incidence of
malaria in children below 5 years of age, had decreased
from 7 to 1.3 episodes per child per year [36].
Study design
The TP1 study enrolled 1113 children [33], while the TP2
study enrolled 1855 children [36]. The TP1 MSP2 MOI
and allelic distributions, previously described [4] was ob-
tained by sampling from the study area sixteen “index
cluster” of contiguous houses, randomly selected from a
total of about 22,000 houses, bimonthly for a year [33].
The random selection of compounds from each of the 16
“index clusters” ensured as much as possible adequate
representation of micro-ecological factors such as water
bodies and vegetation types that are known to influence
malaria transmission. A minimum number of 140 con-
sented participants were selected to represent each cluster.
A total of 308 blood blot filter papers, pre-determined as
positive by microscopy, from children with asymptomatic
malaria and below 5 years of age were sampled ensuring
that each of the 16 clusters were represented in the six bi-
monthly cross-sectional surveys at TP1. MSP2 genotyping
was carried out for all 308 infant samples. Similarly, blood
blot filter papers from 310 children aged below 3 years
with asymptomatic malaria were selected from the same
study area. These (TP2 study samples) were selected via
six bi-monthly cross-sectional sampling and were parasite
positive by microscopy. The molecular studies we de-
scribe, used blood blot filter paper samples from children
in the TP1 and TP2 studies, thus no child participated in
both the TP1 or TP2 molecular studies. The MOI results
from TP1 study were compared with MOI results from
TP2 study. A child was classified as asymptomatic if clin-
ical symptoms or fever was absent (i.e. axillary
temperature < 37.5 °C) but P. falciparum parasites present
by microscopy. All participants whose data are included in
this analyses provided informed consent/assent. The geno-
typing of MSP2 (block 3) was performed on samples from
the TP2 study as described below.
Extraction of genetic material (DNA)
Total deoxy-ribonucleic acid (DNA) was extracted from
dried blood spots on filter paper using the Qiagen
(QIAamp DNA mini kit) DNA extraction protocol for
DNA extraction from filter paper. The manufacturer’s
protocol was followed. The DNA of the MSP2 genotype
was amplified by polymerase chain reactions.
Polymerase chain reaction
Nested polymerase chain reactions (PCR) were carried out
to optimise primers for the FC27 and IC variants of the
MSP2 (Nest 1 forward primer: 5′-ATG AAG GTA ATT
AAA ACA TTG TCT ATT ATA, reverse primer: 5′-CTT
TGT TAC CAT CGG TAC ATT CTT. Nest 2 IC forward
primer: 5′-AGA AGT ATG GCA GAA AGT AAK CCT
YCT ACT, IC reverse primer: 5′-GAT TGT AAT TCG
GGG GAT TCA GTT TGT TCG, FC forward primer: 5′-
AAT ACT AAG AGT GTA GGT GCA RAT GCT CCA,
FC reverse primer: 5′-TTT TAT TTG GTG CAT TGC
CAG AAC TTG AAC). The analyses was carried out based
on procedures previously described [13]. The nest 1 and 2
PCR procedures which were used are outlined. A total reac-
tion volume of 25 μl was used for the nest 1 amplifications.
The nest 1 reaction consisted of 1× Qiagen buffer (contain-
ing 15 mM MgCl2), 1.5 mM MgCl2, 0.50 mM dNTP,
0.4 mM oligonucleotide primers, 1.0 U of Qiagen Taq poly-
merase, and 2 μl template. The PCR was performed at an
initial denaturation of DNA at 95 °C for 3 min, and a latter
denaturation at 95 °C for 45 s. Following the denaturation,
29 cycles of primer annealing at 57 °C for 45 s, and DNA
extension at 72 °C for 1 min were carried out. The final pri-
mer extension after the cycles were carried out at 72 °C for
1 min, and the reaction cooled to 12 °C.
The nest 2 total reaction volume was 25 μl. This
reaction contained 1× Qiagen buffer (containing 15 mM
MgCl2), 1.5 mM MgCl2, 0.50 mM dNTPs, 0.4 mM
oligonucleotide primers, 1.0 U of Qiagen Taq. polymer-
ase, and 2 μl template. The PCR was performed with an
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initial denaturation of DNA at 95 °C for 3 min followed
by 29 cycles of denaturation at 95 °C for 45 s, primer
annealing at 59 °C for 30 s and 1 min of DNA extension
at 72 °C. The final extension was at 72 °C for 10 min
and samples cooled to 12 °C until it was removed from
the thermal cycler.
The nest 2 amplification products were analysed by agar-
ose gel electrophoresis; using 5 μl of the amplified reaction
product in a 2% agarose gel, containing 0.4-mg/ml eth-
idium bromide. A 100 base pair molecular weight marker/
standard was added to the electrophoresis to evaluate the
sizes of amplified PCR products (DNA). Visualisation of
the different sized DNA was performed with an ultraviolet
light transilluminator connected to a desktop computer.
The different sizes of DNA fragments (bands) seen were re-
corded. The total number of bands (parasite genotypes)
from an individual isolate represented an estimate of the
MSP2 MOI for the individual. The mean MOI for MSP2
allelic families (FC27 or IC/3D7) was determined as the
sum of parasite genotypes from the family, divided by the
total number of hosts with positive PCR samples (hosts
with carriage of alleles from the MSP2 allelic family). The
sum of parasite genotypes at a given time point, divided by
the total number of hosts with positive PCR samples at
the time point, represented an estimate of the mean
MSP2 MOI at that time point [4, 37]. Resulting geno-
types were grouped on a bi-monthly (Nov/Dec etc.)
basis for the entire year. The bi-monthly MOI for
TP1 study (calculated as described above) was com-
pared with bi-monthly MOI results obtained for TP2
study. Also, the MOI of the dry season and the MOI
of the wet season were calculated from the resulting
genotypes identified from November to April and
from May to October respectively.
Quality control of PCR
Standard operating procedures and good clinical labora-
tory practices were followed throughout the analyses.
Two negative controls consisting of only reagents (no
template controls), one generated during DNA extrac-
tion and the other at the PCR stage, were added to all
reactions. Positive P. falciparum controls (IC/3D7: 450
base pairs and HB3: 280 base pairs) were sourced from
Malaria Research Reference Reagent Resource Centre.
The samples analyzed by agarose gel electrophoresis in-
cluded a standard base-pair marker. If there was no
amplification, the electrophoresis was repeated using
twice of the quantity of the PCR product. When the
repeated electrophoresis did not show amplification, the
PCRs were repeated using twice of the DNA quantity.
Where non-amplifications persisted after this second
PCR, the amplification was classified as unsuccessful. P.
falciparum species identification was carried out for
unsuccessful amplifications. Unaltered-images of gel
electrophoresed PCR products were scored independ-
ently by two molecular biologists. In the event of
conflicting scores, a third independent molecular
biologist also scored. Same methods were used in the
TP1 analyses [4].
Statistical analysis
The non-parametric Kruskal-Wallis test was used to
compare the bi-monthly arithmetic mean MOI results of
TP2 only for significant differences between at least a
pair of means. The Dunn’s pairwise test was further used
with the Bonferroni adjustment method to detect pair-
wise differences in means. Statistical comparison of TP1
and TP2 MOI were also made using the Wilcoxon rank-
sum test (overall and bi-monthly). All p– values which
were less than 0.05 were statistically significant. STATA
version 14.0 software was used for the statistical
analysis.
Results
A total of 243 successful PCR amplifications were ob-
tained from 308 samples analysed in the TP1 study [4],
while a total of 136 successful PCR amplifications were
obtained from 310 samples analysed at TP2. Samples
which were successfully amplified for analyses in No-
vember/December 2009 (TP2) were 36, while in
January/February, March/April, May/June, July/August,
September/October of 2010 (TP2) the successful ampli-
fications were 25, 29, 13, 13 and 16 respectively.
Successful amplifications for TP1 have previously been
reported [4]. Carriage of 7 genotypes (highest MOI) was
among two children from TP1 and one child from TP2,
all observed in the dry season. Carriage of a single para-
site clone (most frequent) was among 88 children from
TP1 (46 children in dry season, and 42 children in wet
season) and 60 children from TP2 (39 children in the
dry season and 21 in the wet season).
TP1 participants were aged below 5 years, while TP2
participants were aged below 3 years. Comparing the
mean MOI (2.2) for children below age 3 with the mean
MOI (2.3) for children aged between 3 to 5 (<5) years at
TP1, no statistically significant differences (P = 0.56) in
mean MOI was found.
At TP2, the Kruskal Wallis test indicated statistically
significant difference in mean MOI for at least 2 of the
months. The Wilcoxon’s rank sum test showed that the
mean MOI reduced from 2.3 (SD = 1.3) at TP1 to 1.9
(SD = 1.2) at TP2, and this was statistically significant
(P = 0.021). Table 1 shows the significance of the
differences in mean MOIs for the various months.
Distribution of MSP2 diversity by season of year
A comparison of the MSP2 mean MOIs of the two sea-
sons in Table 2, showed reduction in MOI from the dry
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season to the wet season at both TP1 and TP2. This
reduction was significant (p = 0.025) at TP1 but not
significant at TP2 (p = 0.348). During the dry season of
TP1, 32 different IC/3D7 alleles (320 bp to 500 bp) with
a predominant 500 bp allele were identified, while 14
different FC27 alleles (250 bp – 450 bp) with a predom-
inant 300 pb allele were identified (Figs. 1 and 2). During
the wet season at TP1 twenty-one IC/3D7 alleles, (330 -
700 bp) with a predominant 500 bp allele were identi-
fied, while twelve FC27 alleles (180 – 500 bp) with a
predominant 300 pb allele were identified (Figs. 1 and
2). At TP2 sixteen IC/3D7 alleles (280 – 900 bp) with a
predominant 500 bp allele, and sixteen FC27 alleles (250
– 850 bp) with a predominant 500 pb allele were identi-
fied during the dry season (Figs. 1 and 2). Also in the
wet season, thirteen IC/3D7 alleles (120 – 900 bp) with
a predominant 500 bp, and thirteen FC27 alleles (200 –
900 bp), with a predominant 300 bp and 400 pb were
identified (Figs. 1 and 2).
Impact of time on MSP2 diversity
The MSP2 IC/3D7 genotypes were detected more
frequently than FC27 genotypes at both TP1 and TP2
(Table 3). However, whereas the proportion of FC27: IC/
3D7 genotypes was 1:2 at TP1, the proportion of FC27:
IC/3D7 genotypes was 1:1 at TP2 (Table 3). The MSP2
allele fragments were 60 at TP1 and 42 at TP2 (Table 3).
At TP1, the IC/3D7 allele diversity (43 alleles) was
higher than the FC27 allele diversity (17 alleles), and
ranged between 320 bp – 800 bp and 180 bp – 500 bp
respectively (Table 3 and Fig. 2). The predominant
alleles for the IC/3D7 and FC27 allelic families were
500 bp (25.7%) and 300 bp (27.9%) respectively at TP1
(Fig. 2). At TP2 the FC27 allele diversity (22 alleles) was
higher than the IC/3D7 allele diversity (20) and ranged
between 200 bp – 900 bp and 120 bp – 900 bp respect-
ively (Table 3 and Fig. 2). The predominant alleles for
the IC/3D7 and FC27 allelic families were 500 bp
(20.7%) and 500 bp (19.2%) at TP2 (Fig. 2). FC27 alleles
350 bp and 330 bp and IC/3D7 allele 420 bp were
present in the dry seasons but absent in the wet seasons
(transient) at both TP1 and TP2.
Discussion
There is paucity of information regarding epidemio-
logical trends for the independent outcome of malaria
infections or the combination of types or number of
parasite alleles associated with outcome of infection.
Asymptomatic and symptomatic outcomes of malaria
infections have been associated with carriage of distinct
parasite genotypes. Alleles considered important for
erythrocyte invasion and selected as candidate targets
for malaria vaccine development are increasingly being
shown to have distinct characteristics in infection out-
comes. Any unique/distinct patterns of alleles linked to
infection outcome should be reproducible for a given
asymptomatic or symptomatic malaria-cohort regardless
of location, time or intervention. Therefore, we con-
ducted this study to determine whether MSP2 diversity
from children with asymptomatic malaria has pertinent
characteristics in time at the same geographical location.
Table 1 MSP2 mean MOI at TP1 and TP2
Months TP1 TP2
Parasite Genotypes Mean MOI (aSD) Range Parasite Genotypes Mean MOI (SD) Range P-values
Nov/Dec 106 1.9 (0.9) 1–4 96 2.5 (1.6) 1–7 0.07
Jan/Feb 124 2.4 (1.4) 1–7 24 1.2 (0.5) 1–2 0.001
Mar/Apr 127 3.2 (1.5) 1–7 57 2.0 (1.0) 1–4 < 0.001
May/Jun 68 2.1 (1.2) 1–5 20 1.5 (0.8) 1–3 0.123
Jul/Aug 88 2.3 (1.3) 1–6 25 1.9 (1.0) 1–4 0.426
Sept/Oct 37 1.4 (0.9) 1–4 28 1.7 (0.9) 1–3 0.213
Total 550 2.3 (1.3) 1–7 (250) 1.9 (1.2) 1–7 0.021
aSD standard deviation
Table 2 Seasonal MSP2 MOI for TP1 and TP2
Season of year TP1 mean MOI (SD) TP2 mean MOI (SD)
Dry Season (Nov to Apr) 2.4 (1.4) 2.0 (1.3)
Wet Season (May to Oct) 2.0 (1.2) 1.7 (0.9)
P-values 0.025 0.348
0
5
10
15
20
25
30
35
40
FC27 alleles IC/3D7 alleles FC27 alleles IC/3D7 alleles
TP1 TP2
Dry season Wet season
Fig. 1 MSP2 allele diversity for TP1 and TP2
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The results of this study showed significant reduction
in MSP2 MOI from 2.3 in 2004 (TP1) to 1.9 in 2009
(TP2), within a half-decade among children under 5 years
of age who developed asymptomatic malaria. At time
point 1 (TP1) and time point 2 (TP2), the MSP2 IC/3D7
genotypes out-numbered the FC27 genotypes. Variations
in the IC/3D7:FC27 proportions 2:1 at TP1 and 1:1 at
TP2 was observed. The FC27 allele diversity was higher
at TP2 (22 alleles) than at TP1 (17 alleles). Also at TP2,
FC27 allele diversity (22 alleles) was higher than IC3D7
allele diversity (20 alleles). Based on the overall number
of alleles and genotypes observed, the variations in
genotype proportions appears to be primarily driven by
a decrease in the carriage of IC/3D7 alleles. A year to
year variation in malaria epidemiology/transmission
(measured by parasite prevalence) would be gradual
[38], hence the parasite genetic epidemiology. Thus,
these differences in allele diversity may be reflective of
cumulative variations (within 4 years’ interval from TP1
Table 3 Proportions of MSP2 genotypes and alleles at TP1 and
TP2
TP1 TP2
Allelic family FC27 IC/3D7 FC27 IC/3D7
Parasite genotypes 165 385 125 140
Proportion of genotypes 0.3 0.7 0.5 0.5
Number of alleles 17 43 22 20
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d
Fig. 2 MSP2 allelic frequencies at TP1 and TP2. 2a and 2b shows the FC27 allelic frequencies at TP1 and TP2 respectively, while 2c and 2d shows
the IC/3D7 allelic frequencies at TP1 and TP2 respectively
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to TP2), which may be partly due to malaria interven-
tions such as increased use of ITNs and ACTs in
Kintampo [33, 36, 38]. Additional studies to compare
symptomatic and asymptomatic malaria is required to
confirm selectivity of alleles over time and relationships
between decreasing transmission and allelic diversity.
The debate that high MOI in early life is necessary
to reduce risk of developing clinical malaria is on-
going [14, 39, 40]. The significant reduction in MOI
from 2.3 at TP1 to 1.9 at TP2, with a corresponding
decrease in the proportions and number of IC/3D7
genotypes and alleles, among this asymptomatic co-
hort may suggest that specific allele variants with/
without high MOI may be involved in a malaria
infection outcome. Again, additional studies using
sensitive methods for the detection of minor alleles
are required, to clearly determine relationships be-
tween asymptomatic malaria and allelic variations.
There were more single-clone and multi-clone parasite
infections in the dry than in the wet season at both time
points. Measures put in-place to minimize and avoid
template conditions included: use of single template
PCRs, use of a fresh aliquot of primers whenever non-
specific amplifications was detected, paying attention to
negative controls and being mindful of contamination.
The higher MOIs in the dry season compared with the
wet season is consistent with studies among infants in
the Ashanti and Northern Regions of Ghana. These
studies detected more infections in the rainy than in the
dry season but unexpectedly higher MSP diversity in the
dry season than in the rainy season [41] and lowered
MOI in the rainy season with higher polyclonal infec-
tions in the dry seasons [42]. In South-Western
Cameroon where malaria transmission is perennial, a
similar paradox was observed where infants born during
the wet season were more susceptible to malaria infec-
tion while children born in the dry season were pro-
tected [43]. MOIs for residents of Kintampo coincided
with the lowest entomological inoculation rates (EIR), at
the end of the dry season, while the lowest MOIs coin-
cided with the highest EIR at the end of the wet season
[4, 35]. In this study EIR was not measured, however
MOI appears to be high in the dry (low transmission)
season and low in the wet (high transmission) season.
Also, some transient MSP2 alleles which were present in
the dry season were absent during the subsequent wet
season, while other alleles were present in both seasons.
In this study, MSP2 alleles presented during symptom-
atic malaria were not tracked, nevertheless, the essence
of carriage of some alleles throughout both wet and dry
seasons may be as explained by studies carried out by
Sonden et al. (2015) [27] in a high transmission area of
Mali. Their results suggested that “persistent multiclonal
infections carried through the dry season contribute to
protection against subsequent febrile malaria possibly by
maintaining protective immune responses that depend
on ongoing parasite infection” [27]. These observations
are worth noting for a substantive explanation for in-
creased parasite genotypes during low transmission sea-
sons, compared to the high transmission season. As a
marker of exposure to malaria parasites [14], the MOI
can reveal patterns in malaria transmission. Therefore
studies to determine the effect of factors such as vectors
and climate (rainfall and temperature which can influ-
ence changes in malaria transmission [44]) on patterns
of MOI in the dry and wet seasons may be necessary.
Any climatic impacts on MOI may have important
implications (with respect to immune correlates) for the
conduct of some malaria vaccine trials.
Unlike at TP2 where the Qiagen method was used for
DNA extraction, at TP1 the chelex method was used.
The amounts of DNA extracted at TP1 and TP2 could
not be compared quantitatively, and so the ability of one
method to extract DNA more efficiently than the other,
and subsequently introduce bias could not be deter-
mined. Nevertheless no significant differences between
results obtained from the use of these two methods have
been identified, using both buccal cells and blood stains
as the DNA source [45]. Therefore, the change in
method of extracting the DNA at TP2 is not perceived
to bias results. All methods used were comparable.
Electrophoretic variability between TP1 and TP2 during
the establishment of allelic frequencies cannot be
overlooked. The ability to precisely determine the size of
an allele ultimately depends on the method of resolution
of amplified DNA fragments. At present, capillary gel
electrophoresis will be recommended as a reliable
method for accurate sizing of alleles, because it is more
sensitive for detection of accurate DNA fragment
lengths relative to agarose gel electrophoresis.
Conclusion
Findings from this study showed significant reduction
in MSP2 MOI, with a corresponding decrease in the
carriage of IC/3D7 genotypes and allele diversity,
within a half-decade at Kintampo. MSP2 allele diver-
sity was observed in the asymptomatic status but in
different proportions at both time points. A decrease
in the IC/3D7:FC27 proportions from 2:1 at TP1 to
1:1 at TP2, driven mainly by a decrease in carriage of
IC/3D7 alleles was observed. Three MSP2 allele
variants appeared to be transient, while other alleles
persisted throughout both dry and wet seasons. Also,
MSP2 MOI was higher during the low transmission
season than the subsequent high transmission season
at TP1 and TP2. MSP2 allele diversity appeared to be
influenced in a transmission-dependent manner. It
may be that decreases in transmission are related
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specifically to the IC/3D7 allelic family. To clearly de-
cipher relationships between transmission and alleles
will require additional studies, which should employ
the use of sensitive methods and measurements for
the detection of polymorphic parasite markers for
both symptomatic and asymptomatic malaria.
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